Physician profile
Eva K Brown
NPI 1578538153
$2,007.44
in general payments reported to CMS, 2019-2025
16 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $429 · 2023: $325 · 2024: $580 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $628.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.65 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.85 | 2022-2025 | Caplyta |
| Lundbeck LLC | $146.40 | 2021-2024 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $132.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.82 | 2024 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $123.41 | 2021-2024 | Rexulti |
| Tris Pharma INC | $114.24 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $111.18 | 2022-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $91.49 | 2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $45.27 | 2022-2023 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $36.67 | 2024 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $33.25 | 2023 | Adzenys Xr-Odt |
| Corium, LLC | $28.14 | 2023-2024 | Azstarys |
| Adlon Therapeutics L.P. | $25.26 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21.65 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.